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Presymptomatic DNA Testing in BRCA1/2
Invited reactions from the field on the van Oostrom and Tibben paper
The editors of this journal have approached
a number of geneticists and genetic counsellors from
different countries to obtain their comments on the paper
by van Oostrom and Tibben which appeared in a recent
issue of the journal (2004; 2 (1):19-23). In this paper,
the authors proposed a simplified procedure for
presymptomatic testing of BRCA1/2 mutations, which
departs from the ”Huntington-model”. Although the
editor’s survey was not designed to give a representative
overview of international approaches towards
presymptomatic testing for BRCA1 and 2 mutations, it
does give the readers a flavour of the findings and
concerns of some of our colleagues from the field and
highlights some of the similarities and differences
between current practices in different clinics. We do not
fully reproduce all comments here, but rather quote and
summarise selectively the most illustrative remarks and
have asked van Oostrom and Tibben for a response. 
Steven Narod, University of Toronto, Canada,
agrees to use a more a simplified procedure. He reports
that their department sends out paperwork (pedigree
forms and information by mail) about the test design.
They have one pre-test session with their patients and
take blood at that time; test results are given 6 months
later. If the patient wishes they can defer testing or be
offered a second pre-counselling session. Currently,
80% of their patients get their blood taken for testing
at the first appointment, 10% defer and give blood at
a later appointment and 10% decline testing. 
Jill Stopfer, responding on behalf of the University of
Pennsylvania, USA, breast/ovarian cancer genetics clinic
(Barbara Weber, Timothy Rebbeck), reports that their
present testing procedures are similar to those proposed
by van Oostrom and Tibben. The patients typically meet
first with a genetic counsellor or genetic nurse for
pedigree assessment, risk counselling, and pre-test
counselling, if appropriate. They return for a second visit
with a physician at which point an exam is done, risk
assessment further discussed along with medical
recommendations and blood is drawn for testing. Results
are offered either in person, or as part of a scheduled
phone appointment if preferred by the patient. 
Annika Lindblom, from Karolinska Institutet, Sweden,
reports that the model suggested by van Oostrom and
Tibben is in agreement with what her department is
currently doing. As a routine they have one pre-test
counselling session and one post-counselling session
where they offer (and usually it is accepted) referrals to
breast-gynaecological check-up programmes. They also
offer consultations with breast surgeons and
a psychologist. Most often this is not accepted at that
time by the patients, but at a later stage it is. They always
offer carriers a third follow-up visit after the test, which is
most often declined. The patients also get informed that
they are always welcome to contact their department in
person, by telephone or via letter. Their impression is that
this is normally satisfactory. Initially they had more strict
procedures and also protocols for short and long time
follow-up but do not think that it is necessary any more,
which, they believe, is to some extent due to the increased
knowledge about BRCA1-2 and familial breast cancer
in the general population. Their experience will be
reported in a paper (Arver et al, Genetic testing, in press). 
Vìra Krutílková, Vìra Franková and Petr Goetz from
Charles University, Prague, Czech Republic, report that
in their department all patients undergoing the genetic
testing receive at least two genetic counselling sessions
(pre- and post-test). If they feel more extensive
counselling would be needed, patients are encouraged
to undergo another counselling session before or/and
after the test. During the first counselling session patients
are informed about the possibility to use the service of
an associated psychologist and receive his/her
telephone number. They stress that patients should have
the possibility to contact a professional psychologist at
any time during and after the testing procedure. Most
of their patients (80%) retrospectively, did not feel during
and/or after the testing the need for professional
psychological help. Only 6.5% of patients used the
service of a psychologist. The indications mentioned by
van Oostrom and Tibben for the second counselling
session with a genetic counsellor or psychosocial worker
would in their opinion be difficult for the genetic
counsellor to assess. The mandatory inclusion of
another session with a psychosocial worker into the
testing protocol could result into the prolongation of
the pre-test period and therefore also the prolongation
of the initiation of appropriate preventive care. For these
reasons they think that inclusion of another counselling
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session in a pre-test period is not appropriate unless
requested by the patient. In their experience, long-term
follow-up for mutation carriers is needed and highly
appreciated by some patients (30%). 
Gareth Evans from St. Mary’s Hospital in
Manchester, United Kingdom, reports that they do not
insist on 3 sessions, but a minimum of two. It depends
on patient knowledge, a period of reflection and how
certain they are about going ahead. 
Pål Møller from the Radium Hospital in Oslo,
Norway, reports that their department uses a simplified
procedure as well, however he believes that an
international study on current testing practice would
be useful in defining the best practice. 
Andres Metspalu from University of Tartu, Estonia,
agrees that leaving the Huntington model and adopting
a simplified model for BRCA1/2 testing is important
and would be beneficial for patient welfare. 
Håkan Olsson from University Hospital of Lund,
Sweden, reports that in Sweden counselling and testing
in a presymptomatic setting follows the Huntington
model, whereas for cancer patients the simplified
procedure (table 2 in the van Oostrom/Tibben paper)
is closest to practice. He reports that they have very
good experience using those models. 
Dieter Lohmann from Universtiätsklinikum Essen,
Germany, reports on his experience with retinoblastoma
gene testing and concludes that a two-step protocol is
certainly sufficient for hereditary forms of the disease. 
Pavel Elsakov from the Lithuanian Oncology Center
points to the fact that in some countries and institutes,
due to limited finances and inexperience (starting
facilities), women may have to wait a long time before
test results become available and will often postpone
final risk classification to take advantage of the
appropriate clinical treatment. Increased counselling
sessions are likely to increase psychological stress in
the women involved. Doctor Elsakov suggests that this
should be studied and appropriately addressed in
countries/institutes that face this particular problem. 
Ewa Grzybowska from the Cancer Center in Gliwice,
Poland, opts for two-session counselling for HBOC
families. In her experience as a genetic counsellor, most
of the patients coming to a genetic counselling unit think
that one session is enough for all explanations and would
be disappointed very much if she asked them to come
couple of months later to take the blood sample for test.
Pilar Nicolás, University of Deusto, Spain, wishes to
add an ethical and (international) legal perspective to the
discussion, underlining the fact that to carry out the
genetic analyses as part of appropriate genetic
counselling is an obligation established in the international
framework with a moral or judicial binding character. The
following international authorities that have defined ethical
and legal aspects of genetic testing procedures and/or
recommendations on its use are cited by Dr Nicolás: 
1o. International Declaration on human genetic data.
UNESCO (October 16, 2003) (http://portal.unesco.org/
s h s / e n / e v. p h p - U R L _ I D = 1 8 8 2 & U R L _ D O
=DO_TOPIC&URL_SECTION=201.html) 
Article 2. (definitions) ”(xiii) and 1, which define
genetic counselling, stress, its availability when genetic
data are collected and the fact it ”should be
non-directive, culturally adapted and consistent with
the best interest of the person concerned”. 
2o. The 25 recommendations on the ethical, legal
and social implications of genetic testing (European
Community) http://europa.eu.int/comm/research/
conferences/2004/genetic/recommendations_en.htm). 
Recommendation 9, which addresses the availability
of genetic counselling (in the case of highly predictive
genetic tests for serious disorders, the offer of specific
counselling should be mandatory, and patients should
be strongly encouraged to take advantage of it),
educational aspects, exchange of experience at the
European level and development of quality standards. 
3o. Convention for the Protection of Human Rights
and Dignity of the Human Being with regard to the
Application of Biology and Medicine: Convention on
Human Rights and Biomedicine (4.IV.1997) (http://
conventions.coe.int/treaty/en/treaties/html/164. htm) 
Article 12, which defines predictive genetic tests:
”Tests which are predictive of genetic diseases or which
serve either to identify the subject as a carrier of a gene
responsible for a disease or to detect a genetic
predisposition or susceptibility to a disease may be
performed only for health purposes or for scientific
research linked to health purposes, and subject to
appropriate genetic counselling”. 
Dr Nicolás comments that these texts are the basis
to develop concrete protocols that fix the conditions of
the genetic counselling and the ”appropriate”
information that has to be given. 
He also refers to article 5 of the Biomedicine
Convention, which deals with the obligation to obtain
informed consent when one wishes to carry out any
intervention in health and stresses the freedom of the
patient to withdraw consent at any time. It is stated that
in addition to the medical and psychological issues, which
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are discussed with the patients during the presymptomatic
testing procedure, it is necessary to inform them of the
implications for the rights of the patient and others (usually
relatives). Discussion should include the use of the
information obtained, the possibility of exercising the right
not to know (article 10.2 of the Biomedicine Convention
and article 10 of the UNESCO Declaration), possible
relevance for insurance and employment, and the
possible repercussion for the patient’s relatives. 
Rolf H. Sijmons
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Response by Tibben and van Oostrom: 
The comments show that our model reflects the
international clinical practice. Of course, as Nicolás
emphasizes, the counselling should meet the standards
of high care, and the outcome of international debates
needs to be considered. Indeed, distinguished groups
and institutions of high esteem have established guidelines
for appropriate counselling procedures. We favour that
guidelines or a model ought not to be used as
a straitjacket but as a framework of recommended
procedure for careful testing. Following the guidelines
may also provide a safety net that comforts the test
candidate and his or her companion. After 17 years of
experience, most of the difficulties encountered in
predictive testing relate not to laboratory issues, but to
the human aspects of testing. People find it difficult to
process the complex risk figures, to adopt the often
far-reaching treatment or preventive options, and to
consider life style changes. The great challenge is to find
out how to support people in optimally processing the
information that is available, how to enable them to make
the best personal decisions, how to help them to adjust
to the test outcomes and take the appropriate actions,
and how to encourage them to adjust their behaviour to
profit optimally from testing. Moreover, we should realize
that just telling people that they are at risk of developing
a disease is rarely sufficient to change behaviour. 
We have noticed the reluctance in some comments
with regard to psychological support (Lindblom; Krutílková
et al). Indeed, psychological support should not increase
the stress (Elsakov) or delay the testing unnecessarily
(Krutílková et al). As the word ”support” may cause
a misunderstanding, we should differentiate between
psychological assessment and psychological support.
Psychological support is meant to help people to better
prepare them on their way to disclosure, and to adjust
more adequately after they have learned the test results.
Before offering support, however, we need to assess the
test candidate’s vulnerabilities. It is our opinion that
counsellors are the first who should be able to identify
the vulnerable test applicants. In our experience, about
20% of the test candidates might need professional
psychological help, which is similar to the estimation of
Krutílková et al. We agree with them that the assessment
of needs may be difficult for a counsellor. The lessons
from psychological follow-up studies have expanded our
knowledge of who are at risk for adverse reactions. In
addition, tools should be developed that enable
counsellors to identify those people that need referral to
a psychiatrist, psychologist, or psychosocial worker. 
As clinical genetics has adapted the non-directive
tradition (Nicolás), one might argue that a test candidate
can consider the offer of psychological support more or
less voluntarily. In our opinion, however, refusal of the
offer of additional assessment and support cannot be
accepted if there are strong indications for future
maladjustment. If a counsellor estimates that the
consequences of his or her ”treatment”, i.e. genetic
testing, go beyond the test candidate’s capacities to cope
adequately, he or she has the professional responsibility
to account for that and take the appropriate actions,
with the inclusion of – further – psychological assessment
and support. In some cases, the offer of psychological
consultation is therefore not free of obligation. Needless
to say that the prudent and skilful communication of
a referral to a psychosocial worker will increase the
acceptability by the test candidate. 
Iris van Oostrom 
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